Olfr57 Inhibitors
Olfr57, a member of the olfactory receptor family, plays a pivotal role in the recognition and transduction of olfactory signals, contributing to the intricate process of odorant perception. As a G-protein-coupled receptor (GPCR), Olfr57 shares a structural similarity with neurotransmitter and hormone receptors, utilizing a 7-transmembrane domain architecture to facilitate the recognition and transduction of odorant signals.
The potential inhibition of Olfr57 involves targeting specific signaling pathways associated with its function. Methyllycaconitine and CNQX, as receptor antagonists, disrupt cholinergic and glutamatergic signaling pathways, respectively, leading to altered expression and function of Olfr57. Inhibitors such as Iodoacetic Acid and Dantrolene affect Olfr57 indirectly by modulating glycolysis and calcium homeostasis, respectively. PD 98059 and PP2, acting as pathway-specific inhibitors, disrupt the MAPK/ERK and Src kinase signaling cascades, influencing Olfr57 expression and function. Additionally, compounds like Amitriptyline, Niflumic Acid, KN-93, Quinine, Latrunculin A, and GW 5074 target various cellular processes, including monoaminergic signaling, chloride channel activity, CaMKII signaling, potassium channel activity, actin dynamics, and c-Raf signaling, leading to altered expression and function of Olfr57. In summary, the potential inhibition of Olfr57 involves a diverse set of chemical inhibitors that target specific biochemical and cellular pathways associated with olfactory signal transduction. These inhibitors offer insights into understanding and controlling the function of Olfr57 in the complex process of odorant perception.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
6-Cyano-7-nitroquinoxaline-2,3-dione | 115066-14-3 | sc-505104 | 10 mg | $204.00 | 2 | |
AMPA/kainate glutamate receptor antagonist affecting Olfr57 indirectly. CNQX disrupts glutamatergic signaling pathways, leading to altered expression and function of Olfr57. | ||||||
Iodoacetic acid | 64-69-7 | sc-215183 sc-215183A | 10 g 25 g | $56.00 $97.00 | ||
Glycolysis inhibitor influencing Olfr57 indirectly. Iodoacetic Acid disrupts glycolytic pathways, modulating cellular metabolism and consequently leading to altered expression and function of Olfr57. | ||||||
Dantrolene | 7261-97-4 | sc-500165 | 25 mg | $350.00 | 7 | |
Ryanodine receptor antagonist affecting Olfr57 indirectly. Dantrolene disrupts calcium homeostasis, modulating olfactory signaling pathways and consequently leading to altered expression and function of Olfr57. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
MEK inhibitor affecting Olfr57 through the MAPK/ERK pathway. PD 98059 disrupts the MAPK/ERK signaling cascade, leading to altered expression and function of Olfr57 as a downstream consequence of pathway inhibition. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
Src kinase inhibitor influencing Olfr57 through Src signaling pathways. PP2 disrupts Src kinase activity, modulating olfactory signaling pathways and consequently leading to altered expression and function of Olfr57. | ||||||
Amitriptyline Hydrochloride | 549-18-8 | sc-210801 | 1 g | $196.00 | ||
Serotonin and norepinephrine reuptake inhibitor influencing Olfr57 indirectly. Amitriptyline disrupts monoaminergic signaling pathways, leading to altered expression and function of Olfr57. | ||||||
Niflumic acid | 4394-00-7 | sc-204820 | 5 g | $31.00 | 3 | |
Calcium-activated chloride channel blocker affecting Olfr57 indirectly. Niflumic Acid disrupts chloride channel activity, modulating olfactory signaling pathways and consequently leading to altered expression and function of Olfr57. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $178.00 | 25 | |
CaMKII inhibitor affecting Olfr57 through CaMKII signaling pathways. KN-93 disrupts CaMKII activity, modulating olfactory signaling pathways and consequently leading to altered expression and function of Olfr57. | ||||||
Quinine | 130-95-0 | sc-212616 sc-212616A sc-212616B sc-212616C sc-212616D | 1 g 5 g 10 g 25 g 50 g | $77.00 $102.00 $163.00 $347.00 $561.00 | 1 | |
Voltage-gated potassium channel blocker influencing Olfr57 indirectly. Quinine disrupts potassium channel activity, modulating olfactory signaling pathways and consequently leading to altered expression and function of Olfr57. | ||||||
Latrunculin A, Latrunculia magnifica | 76343-93-6 | sc-202691 sc-202691B | 100 µg 500 µg | $260.00 $799.00 | 36 | |
Actin polymerization inhibitor influencing Olfr57 indirectly. Latrunculin A disrupts actin dynamics, modulating cellular processes and consequently leading to altered expression and function of Olfr57. | ||||||